

Hereditary recurrent fever syndromes (*Cont.*):
 familial Mediterranean fever. *See* Familial Mediterranean fever
 genetic considerations in, 2213t
 hyperimmunoglobulinemia D with periodic fever syndrome, 2215
 Muckle-Wells syndrome. *See* Muckle-Wells syndrome (MWS)
 neonatal-onset multisystem inflammatory disease, 2215
 treatment of, 2213t
 tumor necrosis factor- α receptor-associated periodic syndrome, 141, 422, 2214–2215

Hereditary sensory and autonomic neuropathy (HSAN), 2643, 2679–2680t, 2680

Hereditary spherocytosis, 651
 anemia in, 399
 clinical features of, 651–652
 diagnosis of, 652
 genetic considerations in, 651, 652f, 653t
 peripheral blood smear in, 652f
 splenomegaly in, 411
 treatment of, 652

Hereditary stomatocytosis, 81e–4f, 653f, 653t

Hermansky-Pudlak syndrome, 375e–2, 730, 1715, 1949t

Hermaphroditism. *See* Ovotesticular disorders of sexual development

Hernia(s)
 hiatal, 1902, 1902f
 paraesophageal, 1902

Herniation, cerebral, 1772, 1772f

HERNS (hereditary endotheliopathy, retinopathy, nephropathy, and stroke), 2568

Heroin
 action of, 468e–1
 adverse effects of, 462e–20, 462e–20t, 2199
 systems effects of, 468e–2
 toxic levels of, 2765t

Herpangina, 231, 238t, 1293

Herpes gestationis (pemphigoid gestationis), 370t, 372–373

Herpes gladiatorum, 829, 1178

Herpes labialis, 215e–7, 215e–8, 238t, 342f, 829

Herpes simplex virus (HSV)
 adherence of, 145e–1–2, 145e–2t
 gene expression and regulation in, 214e–4
 for gene therapy delivery, 91e–1t
 genome of, 1175
 host response to, 1176
 laboratory identification of, 214e–8, 1180–1181
 ligand-receptor interactions of, 1175
 reactivation mechanisms of, 1175
 structure of, 214e–1f, 1175

Herpes simplex virus (HSV) infections, 1175
 actinomycosis and, 1088
 anorectal, 881, 1178, 1956
 “asymptomatic,” 1177
 in burn wounds, 166e–1
 in cancer patient, 487, 488
 diagnosis of, 342, 1180–1181
 disseminated
 clinical features of, 132t, 134, 258, 266
 in immunosuppressed patients, 1176, 1179–1180
 rash in, 132t
 treatment of, 1181, 1182t

encephalitis
 clinical features of, 1179, 1179f
 complications of, 1179
 differential diagnosis of, 894–896, 895t
 genetic considerations in, 1179
 vs. meningitis, 888
 MRI in, 440e–6f
 pathogenesis of, 1178–1179
 treatment of, 215e–2t, 1179, 1181, 1182t

epidemiology of, 1176–1177
 genital, 341t
 clinical features of, 880f, 880t, 1178, 1178f
 diagnosis of, 881
 epidemiology of, 869, 879, 1177

lymphadenopathy in, 408
 in pregnancy, 50
 prophylaxis for, 215e–7, 215e–8, 1181
 recurrence rates of, 1178
 treatment of, 215e–3t, 215e–7, 215e–8–9, 832t, 1181, 1182t

herpes gladiatorum, 829, 1178
 herpetic whitlow, 1178, 1182t, 1263
 in HIV infection
 perirectal, 1257–1258, 1258f, 1263
 prophylaxis for, 1253t
 treatment of, 1181, 1182t, 1263

in immunocompromised patients, 1176
 keratitis, 200, 215e–3t, 215e–9, 1178, 1182t
 latent, 1176
 meningitis, 892, 908t, 1179
 neonatal, 50, 215e–2t, 1180, 1182t
 oral-facial
 clinical features of, 238t, 1177–1178
 course of, 238t
 pathogenesis of, 233, 827, 829, 1177–1178
 treatment of, 215e–3t, 215e–7, 233, 1182t

pathogenesis of, 1175–1176
 in pregnancy, 50, 1180
 prevention of, 1183
 reactivation of, 1176
 skin manifestations of
 distribution, 341t, 342f
 morphology, 341t
 vesicles/bullae, 132t, 238t, 361, 361t, 827, 829

in transplant recipient
 clinical features of, 921t
 prophylaxis for, 139e–4t, 215e–6, 921
 timing of, 920t
 treatment of, 1181–1183, 1182t

visceral, 1179–1180
 esophagitis, 1179, 1182t, 1896f, 1910
 liver, 1180
 pharyngitis, 231, 1177
 pneumonitis, 1179–1180
 upper respiratory, 1202t

Herpesvirus(es). *See also specific viruses*
 gene expression and regulation in, 214e–4
 host defense inhibition by, 214e–8
 microRNAs in, 214e–6
 protein functions of, 214e–6
 structure of, 214e–1, 214e–1f, 214e–2t, 214e–3f
 transmission of, 214e–6
 viral assembly and egress in, 214e–5

Herpes zoster (shingles), 1184
 clinical features of, 341t, 1184–1185
 abdominal pain, 105
 chest discomfort, 96t, 98
 glossopharyngeal neuropathy, 2649
 neck pain, 122
 neuropathy, 2685
 ocular, 200
 oral manifestations, 237, 238t
 postherpetic neuralgia, 237, 1185, 1186, 2685
 skin manifestations, 25e–8f, 76e–8f, 827, 1184–1185, 1184f
 trigeminal neuropathy, 2646
 diagnosis of, 1185
 differential diagnosis of, 1185
 epidemiology of, 1184
 in HIV infection, 1185, 1185f, 1252t, 1263
 pathogenesis of, 89, 1183
 prevention of, 485t, 929, 1186, 1186t, 1252t
 in transplant recipient, 921, 921t, 925, 1185
 treatment of, 215e–3–4t, 215e–6–7, 215e–8, 832t, 1186

Herpes zoster ophthalmicus, 200, 215e–4t, 1184

Herpes zoster vaccine
 contraindications to, 790t
 recommended administration of, 29t, 84, 787–788f, 893
 storage and handling of, 791

Herpetiform lesions, 340t

Hers disease (type VI GSD), 433e–2t, 433e–4

Hertel exophthalmometer, 207

HES. *See* Hypereosinophilic syndromes (HES)

HESX1 gene, 2256

HESX1 gene mutations, 2325t, 2364t, 2364t

Heterophyes heterophyes, 245e–2t, 765t, 1428t, 1429. *See also* Intestinal flukes

Heteroplasmy/heteroplasmia, 85e–3–4, 85e–5f, 439

Heterosexual precocity, 2380

Heterosexual sexual precocity, 2362

Heterotropia, 197

Heterozygote advantage, 438, 442

Heterozygous, 433f, 435

Heuristics, 19

HEV (hepatitis E virus), 2005f, 2006t, 2010. *See also* Hepatitis E virus (HEV) infection

HEVs (high endothelial venules), 372e–26

Hexacarbons, 2688t, 2689

Hexagonal-phase phospholipids test, 740

Hexokinase (HK) deficiency, 654t

Hexosaminidase A deficiency. *See* Tay-Sachs disease

Hexose-6-phosphate dehydrogenase (H6PDH), 2312

Hexoses, genetic disorders of, 435e–1t

Heyde's syndrome, 731

HF. *See* Heart failure (HF)

HFE gene mutations
 global considerations in, 2519
 in hemochromatosis, 367e–1, 367e–1t, 367e–3
 in liver disease, 1992, 2515, 2518
 in porphyria cutanea tarda, 390, 2515, 2530
 2-HG (2-hydroxyglutarate), 102e–13

hGH-N gene, 401e–3

hGH-V gene, 401e–3

HHIP gene mutations, 1703

HHS (hyperglycemic hyperosmolar state), 2417t, 2420

HHV-6 infection. *See* Human herpesvirus-6 (HHV-6) infection

HHV-7 infection. *See* Human herpesvirus-7 (HHV-7) infection

HHV-8 infection. *See* Human herpesvirus-8 (HHV-8) infection

Hiatal hernia, 1902, 1902f

hic (pneumococcal H inhibitor), 947

Hidradenitis, neutrophilic eccrine, 366, 380

Hidradenitis suppurativa, 1099

HIDS (hyperimmunoglobulinemia D with periodic fever syndrome), 2213t, 2215

HIF-1 (hypoxia-inducible factor-1), 247

HIF (hypoxia-inducible factor) 1a, 333e–4, 392

High-altitude cerebral edema (HACE)
 clinical features of, 247, 476e–1
 epidemiology of, 476e–1
 pathophysiology of, 476e–1–2, 476e–2f
 prevention of, 476e–2
 risk factors for, 476e–1
 treatment of, 476e–2–3, 476e–2t

High-altitude illness, 476e–1
 acute mountain sickness. *See* Acute mountain sickness (AMS)
 cerebral edema. *See* High-altitude cerebral edema (HACE)

chronic mountain sickness, 248, 476e–5

cough, 476e–4

epidemiology of, 476e–1

gastrointestinal, 476e–4

genetic considerations in, 476e–1

hypoxia in, 248

neurologic events, 476e–4–5

physiology of, 476e–1

polycythemia, 399

preexisting medical issues and, 476e–5

psychological/psychiatric problems, 476e–5

pulmonary edema. *See* High-altitude pulmonary edema (HAPE)

 pulmonary edema (HAPE)

pulmonary hypertension, 476e–6

sleep impairment, 476e–4

High-altitude pulmonary edema (HAPE)
 clinical features of, 476e–3, 476e–3f

pathophysiology of, 47e–4, 247, 476e–3–4

prevention of, 476e–4, 1764

risk factors for, 476e–3

treatment of, 476e–2t, 476e–4, 1764

High-amplitude propagated contractions, 265